home / stock / rlmd / rlmd quote
Last: | $ |
---|---|
Change Percent: | -1.10% |
Open: | $42.00 |
Close: | $41.51 |
High: | $42.475 |
Low: | $41.11 |
Volume: | 45,680 |
Last Trade Date Time: | 02/12/2020 04:57:15 pm |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$ | $42.00 | $41.51 | $42.475 | $41.11 | 45,680 | 02-12-2020 |
$ | $42.46 | $41.97 | $43.00 | $41.40 | 58,953 | 02-11-2020 |
$ | $42.31 | $42.52 | $42.86 | $41.86 | 48,692 | 02-10-2020 |
$ | $41.60 | $42.70 | $42.98 | $40.40 | 39,644 | 02-07-2020 |
$ | $40.94 | $41.99 | $42.50 | $40.3151 | 37,853 | 02-06-2020 |
$ | $41.72 | $40.92 | $41.76 | $40.4043 | 107,178 | 02-05-2020 |
$ | $39.68 | $41.79 | $42.00 | $39.41 | 52,877 | 02-04-2020 |
$ | $44.01 | $40.07 | $44.125 | $37.4901 | 257,680 | 02-03-2020 |
$ | $46.77 | $44.35 | $47.00 | $44.35 | 64,856 | 01-31-2020 |
$ | $46.34 | $46.86 | $47.27 | $45.82 | 49,290 | 01-30-2020 |
$ | $46.65 | $46.20 | $47.50 | $45.6235 | 72,251 | 01-29-2020 |
$ | $44.97 | $46.94 | $47.00 | $44.60 | 147,755 | 01-28-2020 |
$ | $42.05 | $44.53 | $44.99 | $42.05 | 145,032 | 01-27-2020 |
$ | $41.01 | $43.30 | $44.00 | $41.01 | 208,611 | 01-24-2020 |
$ | $40.30 | $40.66 | $41.00 | $40.25 | 226,899 | 01-23-2020 |
$ | $40.59 | $40.30 | $41.0996 | $40.12 | 51,759 | 01-22-2020 |
$ | $41.05 | $40.28 | $41.5435 | $40.11 | 50,093 | 01-21-2020 |
$ | $40.30 | $41.07 | $41.57 | $40.25 | 83,570 | 01-20-2020 |
$ | $40.30 | $41.07 | $41.57 | $40.25 | 83,570 | 01-17-2020 |
$ | $39.11 | $40.61 | $41.72 | $37.19 | 154,080 | 01-16-2020 |
News, Short Squeeze, Breakout and More Instantly...
Relmada Therapeutics Inc. Company Name:
RLMD Stock Symbol:
OTCMKTS Market:
Relmada Therapeutics Inc. Website:
Relmada Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year 2023 Financial Results PR Newswire CORAL GABLES, Fla. , March 19, 2024 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addre...
Caleres Inc. (CAL) is expected to report $0.86 for Q4 2024 B Communications Ltd (BCOMF) is expected to report for quarter end 2023-12-31 Dermata Therapeutics Inc. (DRMA) is expected to report for Q4 2023 Core & Main Inc. Class A (CNM) is expected to report $0.34 for Q4 2024 Wi...
Relmada Therapeutics to Report Fourth Quarter and Full-Year 2023 Financial Results and Host Conference Call and Webcast on March 19, 2024 PR Newswire CORAL GABLES, Fla. , March 12, 2024 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biote...